Uncategorized

Data sovereignty in 340B programs refers to the ability of healthcare covered entities to maintain absolute control, privacy, and ownership over their patient and pharmacy claims data while navigating an increasingly complex web of manufacturer restrictions and federal compliance tracking requirements. As pharmaceutical manufacturers demand more granular data, and as state and federal regulations continuously […]

340B eligibility requirements for covered entities are designed to ensure that only specific healthcare providers serving vulnerable populations can access discounted drugs. To qualify, an entity must be a federally qualified health center (FQHC), certain hospitals such as disproportionate share hospitals (DSH), children’s hospitals, or other HRSA-recognized safety-net providers. The entity must be officially registered

The 340B Drug Pricing Program is a U.S. federal program that allows eligible healthcare organizations to purchase outpatient drugs at significantly reduced prices. Because the program involves complex compliance and operational requirements, many hospitals conduct a 340B Program Health Check to evaluate risks, strengthen controls, and ensure their program is operating correctly. The program matters

The shift in 2026 pharmacy benefits, driven by reforms under the Consolidated Appropriations Act, is tightening oversight on Pharmacy Benefit Managers (PBMs) through stronger transparency requirements, rebate reporting, and fiduciary accountability, directly impacting how contracts, pricing models, and reimbursement structures are managed. For 340B stakeholders operating under the 340B Drug Pricing Program, the changes increase

What Is the DSH Calculation Trap and Why Does It Matter? The DSH calculation trap refers to the high-risk scenario where minor errors or systemic shifts in Disproportionate Share Hospital (DSH) calculations cause hospitals to fall below statutory thresholds and lose 340B eligibility. This matters because 340B eligibility is binary; if a hospital drops below

The 340B Drug Pricing Program is a federal initiative that allows eligible healthcare providers known as covered entities to purchase outpatient drugs at significantly discounted prices. Handling Information Collection Requests (ICRs) and navigating hospital eligibility crises are now critical priorities for compliance, operational efficiency, and maintaining financial benefits. Mismanaging 340B requests or failing to meet eligibility requirements can trigger